TCM
MRTX

Tang Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Tang Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,558,059
Closed -$91.5M – 146
2023
Q4 		$91.5M Buy
1,558,059
+1,378,059
+766% +$77.5M 8.46% 1
2023
Q3 		$7.84M Buy
180,000
+100,000
+125% +$3.57M 1.11% 32
2023
Q2 		$2.89M Buy
+80,000
New +$3.3M 0.43% 60
2023
Q1 		– Sell
-60,000
Closed -$2.72M – 122
2022
Q4 		$2.72M Buy
60,000
+40,000
+200% +$2.59M 0.4% 55
2022
Q3 		$1.4M Buy
+20,000
New +$1.48M 0.17% 78
2015
Q2 		– Sell
-388,543
Closed -$11.4M – 9
2015
Q1 		$11.4M Buy
388,543
+150,111
+63% +$3.52M 6.06% 5
2014
Q4 		$4.42M Sell
238,432
-50,000
-17% -$843K 2.42% 8
2014
Q3 		$5.05M Hold
288,432
– – 2.62% 8
2014
Q2 		$5.77M Sell
288,432
-147,411
-34% -$2.85M 2.67% 9
2014
Q1 		$8.31M Sell
435,843
-502,700
-54% -$10.4M 4.03% 8
2013
Q4 		$15.6M Sell
938,543
-242,857
-21% -$4.15M 10.92% 4
2013
Q3 		$17.9M Buy
+1,181,400
New +$11.6M 8.86% 4

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Tang Capital Management's MRTX Position: Q1 2024 in Review

Tang Capital Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 1,558,059 shares — an estimated $91.5M sold.

Tang Capital Management first reported a position in MRTX in Q3 2013 and held it in 12 quarters. The position peaked at $91.5M in Q4 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Tang Capital Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Tang Capital Management sold 1,558,059 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $91.5M.
  • Tang Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2013 and held it in 12 quarters.
  • Tang Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $91.5M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Tang Capital Management's 13F filing for Q1 2024, filed 15 May 2024.